BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the third quarter and nine months ended September 30, 2007. “We are aggressively advancing our broad pipeline of antibody-based therapies for cancer by initiating multiple clinical trials of SGN-40, SGN-33 and SGN-35 over the next six months,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “We will be announcing promising clinical data on both SGN-33 and SGN-35 in the fourth quarter. With SGN-70 poised to enter clinical trials in 2008, and other preclinical projects demonstrating therapeutic potential, our pipeline continues to expand and provide us with additional product development opportunities.”
